Skip to content Home / Companies / TARS TAR
Tarsus Pharmaceuticals, Inc. (TARS) XNAS BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Net insider selling (90d)
Latest TARS Insider Trades
About Tarsus Pharmaceuticals, Inc. (TARS) Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Headquarters IRVINE, CA
Employees 370
Listed 2020
Exchange XNAS https://www.tarsusrx.com SEC filings for TARS on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 6 39,850 $2.45M Grant or award 17 46,599 Option exercise 14 91,210
TARS Insider Transactions (Form 4) 79 54 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 2.
Date Insider Transaction Security Shares Price Value Jun 25, 2026 KG Katherine Goodrich - Director Grant or award Restricted Stock Units 2,417
Recent TARS Form 8-K Filings 5
Recent TARS Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 25, 2026 Mottiwala Aziz Former Officer 81,332 $5.84M View on EDGAR Aug 19, 2026 Mottiwala Aziz Former Officer
TARS Insider Trading - FAQ
What is the latest insider trade for TARS? Tarsus Pharmaceuticals, Inc. (TARS) had 17 insider filings in the last 90 days, with the most recent on 2026-06-29. The full record for TARS runs to 54 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying TARS stock? No insider purchases of TARS were filed in the last 90 days.
How many insiders are selling TARS stock? 6 insider sales of TARS were filed in the last 90 days, totaling $2.45M.
Where can I see TARS SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks TARS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow TARS insider buys? Create a free InsiderAlpha account and press Watch on this page to add TARS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track TARS insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free Jun 17, 2026
Market cap $3.15B
P/E ratio -
Dividend yield -
Average volume 942.9K
52 week high $85.25
52 week low $48.20
Today's high $72.03
Today's low $70.73
Open $71.19
Volume 615.7K
Previous close $71.92
Shares outstanding 43.88M Market cap
$3.15B
370 employees
TARS Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 6 sales totaling $2.45M.
Most-Active TARS Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Jun 25, 2026 KG Katherine Goodrich - Director Grant or award Stock Option (right to buy) 3,837 $0.00 -
Jun 25, 2026 AG Andrew D. Goldberg - Director Grant or award Stock Option (right to buy) 3,837 $0.00 -
Jun 25, 2026 AG Andrew D. Goldberg - Director Grant or award Restricted Stock Units 2,417 $0.00 -
Jun 25, 2026 SM Scott W. Morrison - Director Grant or award Stock Option (right to buy) 3,837 $0.00 -
Jun 25, 2026 SM Scott W. Morrison - Director Grant or award Restricted Stock Units 2,417 $0.00 -
Jun 25, 2026 BC Bhaskar Chaudhuri - Director Grant or award Stock Option (right to buy) 3,837 $0.00 -
Jun 25, 2026 BC Bhaskar Chaudhuri - Director Grant or award Restricted Stock Units 2,417 $0.00 -
Jun 25, 2026 WY Wendy L. Yarno - Director Grant or award Restricted Stock Units 1,209 $0.00 -
Jun 25, 2026 WY Wendy L. Yarno - Director Grant or award Stock Option (right to buy) 3,837 $0.00 -
Jun 25, 2026 WY Wendy L. Yarno - Director Grant or award Restricted Stock Units 2,417 $0.00 -
Jun 25, 2026 DP David E. I. Pyott - Director Grant or award Restricted Stock Units 806 $0.00 -
Jun 25, 2026 DP David E. I. Pyott - Director Grant or award Stock Option (right to buy) 3,837 $0.00 -
Jun 25, 2026 DP David E. I. Pyott - Director Grant or award Restricted Stock Units 2,417 $0.00 -
Jun 25, 2026 WL William J. Phd Link - Director Grant or award Stock Option (right to buy) 3,837 $0.00 -
Jun 17, 2026 BA Bobak R. Azamian - Officer Open-market sale Common Stock 4,582 $61.24 $281K
Jun 17, 2026 BA Bobak R. Azamian - Officer Open-market sale Common Stock 5,418 $61.81 $335K
Jun 16, 2026 JF Jeffrey S. Farrow - Officer Open-market sale Common Stock 14,396 $60.95 $877K
Jun 15, 2026 JF Jeffrey S. Farrow - Officer Option exercise Restricted Stock Units 27,881 $0.00 -
Jun 12, 2026 SM Scott W. Morrison - Director Option exercise Restricted Stock Units 2,954 $0.00 -
Jun 12, 2026 BC Bhaskar Chaudhuri - Director Option exercise Restricted Stock Units 2,954 $0.00 -
Jun 12, 2026 KG Katherine Goodrich - Director Option exercise Restricted Stock Units 2,954 $0.00 -
Jun 12, 2026 WY Wendy L. Yarno - Director Option exercise Common Stock 2,954 - -
Jun 12, 2026 WY Wendy L. Yarno - Director Option exercise Restricted Stock Units 2,954 $0.00 -
Jun 12, 2026 AG Andrew D. Goldberg - Director Option exercise Restricted Stock Units 2,954 $0.00 -
Apr 24, 2026 DP David E. I. Pyott - Director Option exercise Restricted Stock Units 1,383 $0.00 -
Mar 17, 2026 BW Bryan Wahl - Officer Open-market sale Common Stock 4,084 $69.42 $284K
Mar 18, 2026 BW Bryan Wahl - Officer Open-market sale Common Stock 4,125 $68.71 $283K
Mar 19, 2026 BW Bryan Wahl - Officer Open-market sale Common Stock 4,231 $67.00 $283K
Mar 17, 2026 AM Aziz Mottiwala - Officer Open-market sale Common Stock 4,286 $69.42 $298K
Mar 18, 2026 AM Aziz Mottiwala - Officer Open-market sale Common Stock 4,330 $68.71 $298K
Mar 19, 2026 AM Aziz Mottiwala - Officer Open-market sale Common Stock 4,440 $67.00 $297K
Mar 17, 2026 JF Jeffrey S. Farrow - Officer Open-market sale Common Stock 2,111 $69.42 $147K
Mar 18, 2026 JF Jeffrey S. Farrow - Officer Open-market sale Common Stock 2,133 $68.71 $147K
Mar 19, 2026 JF Jeffrey S. Farrow - Officer Open-market sale Common Stock 2,186 $67.00 $146K
Mar 17, 2026 BA Bobak R. Azamian - Officer Open-market sale Common Stock 10,972 $69.42 $762K
Mar 18, 2026 BA Bobak R. Azamian - Officer Open-market sale Common Stock 11,667 $68.71 $802K
Mar 19, 2026 BA Bobak R. Azamian - Officer Open-market sale Common Stock 11,964 $67.00 $802K
Mar 15, 2026 BW Bryan Wahl - Officer Option exercise Common Stock 24,236 - -
Mar 15, 2026 BW Bryan Wahl - Officer Option exercise Restricted Stock Units 4,790 $0.00 -
Mar 15, 2026 BW Bryan Wahl - Officer Option exercise Restricted Stock Units 7,248 $0.00 -
Mar 15, 2026 BW Bryan Wahl - Officer Option exercise Restricted Stock Units 7,176 $0.00 -
Mar 15, 2026 BW Bryan Wahl - Officer Option exercise Restricted Stock Units 5,022 $0.00 -
TEC 
